TROG Cancer Research
Members Login   CQMS Login

Closed lung trials

Trials closed to recruitment

TROG 09.02 (CHISEL) - this study investigates whether radiotherapy given as three large doses over a period of two weeks (hypofractionated radiotherapy) is more effective than standard radiotherapy for patients with non-small cell lung cancer that has not spread beyond the lung.

Primary sponsor: TROG

Completed trials

TROG 16.01 (NIVORAD) - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

TROG 13.01 (SAFRON) - Assessing stereotactic body radiotherapy for side effects, quality of life, cost effectiveness and resource use.

TROG 03.07 - A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer

TROG 99.05 - Tumour Volume as an Independent Prognosis Factor in Patients with Non-Small Cell Lung Cancer: A Protocol for a Progressive Database

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.